Bloomsbury Genetic Therapies ("Bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies.
Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare disease expertise from the Company’s academic founders, Professor Paul Gissen, Professor Manju Kurian, Professor Ahad Rahim and Professor Simon Waddington. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.
Location: United Kingdom, England, London
Member count: 1-10
Total raised: $5.597017M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 28.10.2022 | UCL Techno... | ucltf.co.u... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 07.10.2022 | Seed | $5.597017M | - | ucltf.co.u... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 01.02.2023 | Bloomsbury... | Read the full story from Blo... | - | - | ucltf.co.u... |
| 06.10.2022 | Bloomsbury... | Bloomsbury’s innovative appr... | - | - | ucltf.co.u... |
| 06.10.2022 | Bloomsbury... | Bloomsbury’s innovative appr... | - | - | ucltf.co.u... |
| - | Bloomsbury... | “Bloomsbury Genetic Therapies ... | - | - | fastfounde... |